Juliette McHardy, Adriana Blanco Marquizo, Douglas Bettcher, Emmanuela Gakidou
{"title":"Policy view: worldwide patterns of tobacco use with recommendations for tobacco control","authors":"Juliette McHardy, Adriana Blanco Marquizo, Douglas Bettcher, Emmanuela Gakidou","doi":"10.1016/s2213-2600(25)00172-9","DOIUrl":null,"url":null,"abstract":"The global epidemic of tobacco-related diseases continues to be a major health and economic issue. The WHO Framework Convention on Tobacco Control (WHO FCTC), adopted in 2003, is a legally binding treaty aimed at reducing the demand for and supply of tobacco products, with 183 Parties, comprising countries and the EU, covering more than 90% of the world's population. This Policy View presents an analysis of the global patterns of tobacco use, the effects of the WHO FCTC and measures implemented for tobacco control, barriers to progress, and the principal ways forward. Our paper focuses on the overarching challenge of uneven WHO FCTC and tobacco control implementation across countries and policy domains, as well as related implementation barriers of insufficient funding and tobacco industry interference in policy development and implementation. The necessary response is the concerted application of WHO FCTC Article 5.3 protections against the political and scientific practices of the tobacco industry and its affiliates. This response to industry's interference needs to be supported by efforts to increase funding and strengthen political will to act in favour of health. A further challenge is the aggressive commercial marketing—particularly to young people and with unproven health claims—of new tobacco products, such as heated tobacco products, and new nicotine products, such as e-cigarettes. This issue needs to be met with the extension of tobacco control measures to these newproducts and concerted efforts to prevent industry interference.","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"109 1","pages":""},"PeriodicalIF":32.8000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2213-2600(25)00172-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
The global epidemic of tobacco-related diseases continues to be a major health and economic issue. The WHO Framework Convention on Tobacco Control (WHO FCTC), adopted in 2003, is a legally binding treaty aimed at reducing the demand for and supply of tobacco products, with 183 Parties, comprising countries and the EU, covering more than 90% of the world's population. This Policy View presents an analysis of the global patterns of tobacco use, the effects of the WHO FCTC and measures implemented for tobacco control, barriers to progress, and the principal ways forward. Our paper focuses on the overarching challenge of uneven WHO FCTC and tobacco control implementation across countries and policy domains, as well as related implementation barriers of insufficient funding and tobacco industry interference in policy development and implementation. The necessary response is the concerted application of WHO FCTC Article 5.3 protections against the political and scientific practices of the tobacco industry and its affiliates. This response to industry's interference needs to be supported by efforts to increase funding and strengthen political will to act in favour of health. A further challenge is the aggressive commercial marketing—particularly to young people and with unproven health claims—of new tobacco products, such as heated tobacco products, and new nicotine products, such as e-cigarettes. This issue needs to be met with the extension of tobacco control measures to these newproducts and concerted efforts to prevent industry interference.
期刊介绍:
The Lancet Respiratory Medicine is a renowned journal specializing in respiratory medicine and critical care. Our publication features original research that aims to advocate for change or shed light on clinical practices in the field. Additionally, we provide informative reviews on various topics related to respiratory medicine and critical care, ensuring a comprehensive coverage of the subject.
The journal covers a wide range of topics including but not limited to asthma, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), tobacco control, intensive care medicine, lung cancer, cystic fibrosis, pneumonia, sarcoidosis, sepsis, mesothelioma, sleep medicine, thoracic and reconstructive surgery, tuberculosis, palliative medicine, influenza, pulmonary hypertension, pulmonary vascular disease, and respiratory infections. By encompassing such a broad spectrum of subjects, we strive to address the diverse needs and interests of our readership.